Johnson & Johnson Vision Receives Approval in Canada for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Management

Johnson & Johnson Vision received approval from Health Canada for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Management. These orthokeratology (ortho-k) lenses are worn overnight for the control of myopia and are specifically designed to match a patient’s eye based on its unique corneal shape and prescription to temporarily reshape the cornea.[1] This approval follows Health Canada’s approval of Acuvue Abiliti 1-Day Soft Therapeutic Lenses for Myopia Management in September 2021.

“Johnson & Johnson Vision is helping to address the dramatically increasing rates of myopia by bringing forward innovate products, services and solutions to help control the disease and give families a chance at better eye health in the future,” Chandra Mickles, OD, MS, FAAO, FSLS, North America Professional Education Lead, Myopia, Johnson & Johnson Vision, said in a company news release. “With Abiliti Overnight lenses and Abiliti 1-Day lenses, we are adding to our growing suite of Abiliti products to help change the trajectory of myopia.”

Clinical studies have shown Abiliti Overnight lenses are a successful option for controlling the progression of myopia. The lenses are simple to prescribe by inputting the patient’s refraction, iris diameter and corneal topography data into the FitAbiliti software, which evaluates and recommends a lens with a first fit success rate of approximately 90%. [6] Abiliti Overnight lenses will be available in two different contact lens designs: Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Management, and Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Management for Astigmatism.[2]

Each annual purchase of an Abiliti product will provide a free comprehensive eye health exam to a child in need through Sight For Kids – a joint program from Johnson & Johnson Vision and the not-for-profit Lions Clubs International Foundation (LCIF). Sight For Kids is one of the largest-known, school-based eye health programs that mobilizes LCIF and eye care professionals to provide comprehensive eye health services in low-income schools around the world.

The Health Canada approval of Abiliti Overnight lenses stems from the collaboration of Johnson & Johnson Vision with Menicon to bring forward therapeutic contact lenses for myopia control under the Abiliti brand. Abiliti Overnight lenses are now available in select parts of Canada. Families and eye care professionals who want more information can visit www.seeyourabiliti.com.

References

^§ Johnson & Johnson MedTech comprises the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s MedTech segment.

[1] Data on File 2022. Menicon Design History file

[1]Data on File 2022. Instructions for Use (Canada)

[1] Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, et al. Short-term changes in ocular biometry and refraction after discontinuation of long-term orthokeratology. Eye Contact Lens. 2014;40(2):84-90. doi: 10.1097/ICL.0000000000000014.

[1] Cho P, Cheung SW. Discontinuation of orthokeratology on eyeball elongation (DOEE). Contact Lens Anterior Eye. 2017;40(2):82-87. doi: 10.1016/j.clae.2016.12.002.

[1] Lau JK, Vincent SJ, Cheung SW, et al. The influence of orthokeratology compression factor on ocular higher-order aberrations. Clin Exp Optom. 2020;103(1):123-128. doi: 10.1111/cxo.12933.

[1] Wan K, Lau JK, Cheung SW, et al. Refractive and corneal responses of young myopic children to short-term orthokeratology treatment with different compression factors. Contact Lens Anterior Eye. 2020;43(1):65-72. doi: 10.1016/j.clae.2019.10.134.

[1]Flitcroft DI et al. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31(6):622-660.

[1] Donovan L, Sankaridurg P, Ho A et al. Myopia progression rates in urban children wearing single-vision spectacles. OVS 2012;89(1):27-32.

[1] Pärssinen O, Kauppinen M. Risk factors for high myopia: a 22-year follow-up study from childhood to adulthood. Acta Ophthalmologica. 2019;97(5):510-518.

[1] Holy C, Kulkarni K, Brennan NA. Predicting Costs and Disability from the Myopia Epidemic – A Worldwide Economic and Social Model. Invest Ophthalmol Vis Sci.2019;60(9):5466-5466.

[1] Hu Y, Ding X, Guo X, Chen Y, Zhang J, He M. Association of Age at Myopia Onset with Risk of High Myopia in Adulthood in a 12-Year Follow-up of a Chinese Cohort. Jama Ophthalmol. 2020;138(11):1129-1134. doi:10.1001/jamaophthalmol.2020.3451.

[1] Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo K, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 to 2050. Ophthalmol. 2016;123(5):1036-1042. doi: 10.1016/j.ophtha.2016.01.006.

[1] Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci [Internet]. 2012/09/13. 2012;53(11):7077–85.

[1] Chen C, Cheung SW, Cho P. Myopia control using toric orthokeratology (TO-SEE study). Invest Ophthalmol Vis Sci [Internet]. 2013/09/05. 2013;54(10):6510–7.

[1] Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R. Orthokeratology vs. spectacles: adverse events and discontinuations. Optom Vis Sci. 2012 Aug;89(8):1133-9.